Splice variants have been shown to play an important role in tumor initiation and progression and can serve as novel cancer biomarkers. However, the clinical importance of individual splice variants and the mechanisms by which they can perturb cellular functions are still poorly understood. To address these issues, we developed an efficient and robust computational method to: (1) identify splice variants that are associated with patient survival in a statistically significant manner; and (2) predict rewired protein-protein interactions that may result from altered patterns of expression of such variants. We applied our method to the lung adenocarcinoma dataset from TCGA and identified splice variants that are significantly associated with patient survival and can alter protein-protein interactions. Among these variants, several are implicated in DNA repair through homologous recombination. To computationally validate our findings, we characterized the mutational signatures in patients, grouped by low and high expression of a splice variant associated with patient survival and involved in DNA repair. The results of the mutational signature analysis are in agreement with the molecular mechanism suggested by our method. To the best of our knowledge, this is the first attempt to build a computational approach to systematically identify splice variants associated with patient survival that can also generate experimentally testable, mechanistic hypotheses. Code for identifying survival-significant splice variants using the Null Empirically Estimated P-value method can be found at https://github.com/thecodingdoc/neep. Code for construction of Multi-Granularity Graphs to discover potential rewired protein interactions can be found at https://github.com/scwest/SINBAD. Presentation slides are found at https://github.com/scwest/RECOMB-CBB 2019 NEEP.
Large-scale cancer sequencing initiatives have opened up a window into the genome of 2 individual cancers, offering unprecedented opportunities for studying the functional 3 consequences of molecular alterations in human cancers [1] . However, despite new 4 evidence highlighting the importance of cancer-specific splice variants in tumor 5 initiation and progression, the role played by splice variants in the biology of human 6 cancers and patient survival is still poorly understood. 7 To address this need, we developed a novel, statistically robust, multi-granular 8 method to identify splice variants that are significantly associated with cancer patient 9 survival. After clinically important splice variants are detected, our approach identifies 10 variant-specific losses and gains of protein domains that can potentially rewire the 11 cellular interactome, enabling a mechanistic interpretation of the role played by these 12 splice variants. We applied this approach to Lung Adenocarcinoma (LUAD) using data 13 from The Cancer Genome Atlas (TCGA), based on the clinical importance of the 14 disease, the large number of observed point mutations that can lead to aberrant splicing, 15 and the spread in patient survival time. 16 With lung cancer as the leading cause of cancer-related deaths [2] , novel treatments 17 are constantly developed to improve patient survival while reducing the toxicity and 18 side-effects of conventional chemotherapy. In this regard, molecular targeted therapy is 19 arguably one of the most investigated new paradigms in oncology. The general strategy 20 in targeted therapy is to use small molecules to inhibit specific pathways important for 21 cancer cell survival and invasiveness. [3] . However, for molecular targeted therapy to be 22 successful, it is important to identify highly specific molecular mechanisms that lead to 23 tumor survival and metastasis. For this reason, cancer-specific alternative splicing has 24 received increasing attention for its role in tumor formation [4, 5] , and methods to target 25 splicing in cancer have recently been proposed [6] using RNAseq data. 26 While some argue in favor of the robustness of gene level analysis of RNAseq 27 data [7] , splice variant analysis offers unique information [8] . Sebestyén et al. developed 28 a computational method to identify splicing signatures in cancers using TCGA data, 29 showing that splicing signatures can be used to distinguish tumor from normal 30 samples [9] . Yang and co-workers developed a web server called ISOexpresso to identify 31 predominantly expressed isoforms in TCGA data [10] . Recent work by knowledge this is the first attempt at building a high-throughput approach for survival 44 analysis at the gene or splice variant level for early integration with domain sources.
45
Another important requirement for confident knowledge extraction is that of 46 robustness, defined as stability of the results with respect to small changes in the 47 parameters of the method. Non-parametric survival analysis requires a threshold that 48 splits patients into subpopulations (e.g. an expression threshold). Previously, 49 high-throughput survival analysis using arbitrary thresholds were shown to be sensitive 50 to changes in patient groups [14] . One known approach for increasing this robustness is 51 to find the minimum p-value by sampling multiple thresholds. However, this produces 52 p-values that are non-uniform and skewed. Lausen and Schumacher examined this 53 problem for the logrank test, developing an equation for estimating the corrected 54 p-values [15] . Yet, this type of correction method was not developed for high-throughput 55 analysis, where multiple hypothesis testing is required and is dependent on very small 56 changes of individual p-values. To overcome these issues, we developed a reliable and 57 high-throughput survival analysis method called NEEP (null empirically estimated 58 p-values). This method requires no distribution assumptions, guarantees statistically 59 valid p-values, and may be implemented in a high-throughput way. 60 We applied this method to the LUAD RNAseq dataset from TCGA to conduct 61 survival analysis at the splice variant level, identifying variants that are significantly 62 associated with patient survival. Then, we integrated these results with protein-domain 63 annotation and protein-protein interaction data to provide a mechanistic interpretation 64 for the potential role played by these clinically relevant splice variants in tumor 65 formation and progression. More specifically, we identified variants that lose or gain 66 protein domains involved in mediating protein-protein interactions. We refer to this 67 integration approach as a multi-granularity graph (MGG). Fig. 1 shows the overall 68 workflow of the method.
69
In the absence of a gold standard, we conducted case study analysis with literature 70 review to assess the biological plausibility of the inferred graphs. In summary, our main 71 contributions are the following: (1) we use the splice variant granularity level as a way 72 to identify changes in protein mechanisms that can affect patient survival; (2) we 73 present a novel, computationally efficient, and robust method to perform 74 high-throughput survival analysis; and (3) we integrate multiple data types for inferring 75 biologically plausible and potentially actionable molecular targets in lung cancer.
76

Results
77
NEEP identifies splice variants significantly associated with 78 patient survival 79 One of the contributions of this work is the development of a statistically robust and 80 computationally efficient method to identify optimal expression thresholds that yield 81 minimum p-values when performing survival analysis over a large number of transcripts. 82 The efficiency of the NEEP method is due to the fact that we can estimate empirical 83 p-values for all transcripts by computing only one null distribution, as opposed to 84 having to perform sample permutations for every transcript (as discussed in detail in 85 Materials and Methods). To visually show this, we plot the p-value distributions of 100 86 randomized gene expression patterns of size 1000, against 20 simulated null 87 distributions of size 1000 obtained by shuffling samples (Fig 2A) . The overlap between 88 these distributions visually confirms that the same null distribution can be utilized 89 across all expression patterns without the need for expensive sample permutations for 90 every transcript. 91 We ran NEEP using 10 randomly generated null distributions of 1,000,000 isoform Workflow for generating multi-granularity graphs (MGGs). Using the NEEP method significant splice variants were calculated, utilizing clinical data, the complementary-DNA reference library, and RNA-Seq data from Ensembl and TCGA. Multi-granular graphs were constructed for known protein-protein interactions from BioGRID, mapped from Ensembl to at least one significant splice variant. Domains were predicted for each splice variant using HMMER3 and Pfam. Gained and ghost domains were identified in splice variants associated with survival. Final MGGs represent potential lost or gained protein interactions associated with patient survival. simulations. In all 10 repetitions, there were 181 NEEP significant (FDR < 0.1) splice 93 variants from the LUAD dataset. Since the order of splice variants in NEEP does not 94 depend on the null but only their statistical significance does, these 181 splice variants 95 were identical each time. The mean hazard ratio of the significant splice variants was 96 3.122 and the minimum was 2.18.
97
The distribution of all the p-values is nearly uniform, as can be seen in Fig 2B. The 98 small deviation of low p-values from the uniform distribution is due (as expected) to the 99 significant splice variants.
100
Case study of multi-granular graphs linked to DNA repair 101 After identifying splice variants significantly associated with survival, we followed the The overlap between the two groups of density plots empirically confirms that the null distribution is the same for all expression patterns, given identical clinical data.
obtained 50 MGGs (the complete list is available in S3 File). We first checked whether 108 the MGGs we obtained were representative of the full set of significant splice variants 109 identified by NEEP. To do that, we performed Gene Ontology enrichment analysis on 110 NEEP significant genes, NEEP significant isoforms, and genes represented in MGGs, as 111 discussed in S1 File. All GO enrichment term groups obtained at the gene or isoform 112 levels were also present in the MGGs, as shown in S1 Fig crosslinks.
137
RAD23A-201 loses interaction with CHEK1 proteins 138
The RAD23A-201 isoform does not include the UBA 2 domain, which is found in all of 139 the other RAD23A isoforms. The survival analysis indicates that a high expression of 140 RAD23A-201 is associated with lower patient survival. RAD23A operates by bringing 141 proteins marked for ubiquitination to the proteasome, avoiding its own degradation.
142
Without UBE 2 RAD23A is ubiquitinized, preventing its role in nucleotide excision 143 DNA repair and protein degredation [36] . Further, without the UBA 2 domain, the PPI 144 between RAD23A and CHEK1 via the DDI between UBE 2 and Pkinase will not occur. 145 It may be possible that RAD23A phosphorylates CHEK1 since its cousin, RAD17, is a 146 known phosphorylator of CHEK1 [37] . However, this is unlikely since RAD23A is 147 known to function primarily through its association with the proteasome [38] . The 148 inhibition of the PPI with CHEK1 may prevent degredation of CHEK1. Under several 149 circumstances CHEK1 promotes tumor growth and increases therapy resistance [37] . 150 Thus the reduction of RAD23A with longevity could inhibit CHEK1 degredation and 151 As shown in Table 1 , RAD51C-202 is associated with COSMIC mutation signatures 173 2, 3, 11, 12, 16, 17, and 23. Of particular interest, signature 3 (Fig 4) is reported by 174 COSMIC as associated with failure in DNA double-strand breaks in homologous 175 recombination. Indeed, the results of the Mood's test indicate that signature 3 is more 176 prevalent in patients with high expression of RAD51C-202 than in patients with low 177 expression (p < 0.0232, Fig 4) . RAD51C-202 had the highest association with COSMIC 178 signature 2, which is known to be caused by AID/APOBEC activity. However, we could 179 not find more information from the literature regarding this particular signature. Unknown The difference between the mean contributions of low from high RAD51C-202 expression groups to each significant mutation signature is reported. Signature 4, associated with smoking, is not significant.
180
Since smoking is commonly associated with lung cancer and may cause particular 181 mutation patterns, the relationship between RAD51C-202 with signature 3 could be 182 confounded by smoking. However, smoking does not appear to be a confounding factor 183 in RAD51C-202 association with COSMIC gene signatures. As can be seen in Table 2 , 184 no smoking variable was significantly different between patients with low and high 185 expression of RAD51C-202. Further, signature 4 contribution (found in smokers) was 
Robustness of NEEP to changes in patient population
192
We conducted 100 simulations by removing 5% and 10% of the patients at random prior 193 to running NEEP. We compared the rank of the significant isoforms observed in the full 194 dataset to their rank in the simulations. Fig 5A shows Further, splice variants with lower observed rank had lower variance in the simulations. 198 In addition and as expected, ranks in the 5% simulations were much lower than the observed rank is the same as the simulated rank. Once again we see that splice variants 202 with low observed rank have lower simulation variance than variants of higher rank.
203
Mean Spearman rank correlations between the entire set of observed splice variants and 204 May 3, 2019 8/16
the 5% and 10% simulation rounds were 0.861 and 0.931, respectively. Overall, these 205 results suggest that the NEEP method is fairly robust to removal of patient samples. The central 50 ranks for the 100 simulations of each of the 181 significant splice variants are plotted as a shaded range according to their mean simulated rank, separately for the 5% simulations (red) and the 10% simulations. Each of these ranges correspond to an observed (non-simulated) rank, which is plotted as a dot along the same x-axis. The 5% simulation ranges have lower means of simulation rank than the 10% simulation ranges; thus the red dots are closer to the identity line. The maximum mean of the simulation rank is lower for the 5% simulations; thus the red shade ends much sooner than the blue shade. (B) The density plot of the observed vs. simulation pairs for the 181 significant splice variants.
Discussion
207
An exploratory survival analysis must be high-throughput to span all genes/splice 208 variants (in this study, 21,100 genes and 69,561 splice variants). Cox regression and 209 Kaplan-Meier (KM) curves are two options. We chose to avoid Cox regression for two 210 reasons. First, we violate the Cox regression assumption that the mechanism of 211 censoring is not related to patient survival, as patients who survive to the end of the 212 study will have a higher survival rate than the overall population at the outset. As 
219
The hypothesis of the KM logrank test is also better suited to this problem than Cox 220 regression: Cox regression tests against the null that the variability of the survival 221 cannot be explained by the variability of the splice variant, whereas the KM logrank 222 test compares low against high expression. Therefore, each KM hypothesis is associated 223 with the maximum difference between two survival curves, and exact delineations of low 224 and high expression are extracted.
225
A current limitation of our approach is that the multi-granularity graphs only 226 highlight splice variants that can gain or lose protein-protein interactions as a result of 227 gains/losses of protein domains. Protein-DNA, protein-RNA, and protein-ligand 228 interactions are not considered. We plan to extend our work in this direction in the near 229 future.
230
In conclusion, we presented NEEP, a novel computational method to systematically 231 identify splice variants significantly associated with patient survival. An important 232 advantage of NEEP over the existing methods is that the optimal expression threshold 233 May 3, 2019 9/16
to separate patients into better vs. worse survival groups is automatically detected by 234 the method, and the resulting p-values are uniformly distributed under the null 235 hypothesis, allowing for proper multiple hypothesis correction.
236
By applying our method to the TCGA lung adenocarcinoma dataset, we identified 237 several splice variants that significantly correlate with patient survival. We then built 238 multiparted, multi-granular graphs (splice variant-domain-domain-splice variant) that 239 allowed us to identify putative losses and gains of protein-protein interactions associated 240 with these splice variants. Several of these variants turned out to be implicated in DNA 241 repair through homologous recombination. To computationally verify this, we 242 performed a mutational signature analysis that supported the molecular mechanism 243 suggested by the multi-granular graphs.
244
Materials and methods
245
Data retrieval and transcriptome profiling 246 We downloaded the TCGA Lung Adenocarcinoma (LUAD) dataset from the Cancer 247 Genomics Hub (CGHub). Of the 515 patients with RNA-Seq data, 75 were removed due 248 to clinical annotations suggesting possible confounding factors like "Prior malignancy" 249 or "Synchronous malignancy". Eight patients were removed due to missing survival 250 data, resulting in 432 total patients. To reconstruct splice variant abundance estimates, 251 the TCGA BAM files were reverted back to fastq format using SAMtools [16] . 252 We used Salmon [17] with default parameters to estimate transcript-level abundances 253 based on the Ensembl 91 cDNA library. Non-alignment methods such as Salmon offer 254 accurate abundance estimates at the splice variant level [18] . In addition, Salmon 255 performed best during a comparison of alignment-free methods [19] . Using Ensembl 256 gene/splice variant mapping, we summed splice variant abundances to estimate gene 257 abundance. TPM values were used to represent the gene/splice variant abundances. We 258 note that since non-parametric survival analysis utilizes two Kaplan-Meier curves for 259 each gene/splice variant (one for high abundance and one for low abundance), the 260 choice of using counts, FPKM or TPM will result in identical logrank p-values.
261
High-throughput survival analysis 262 We performed non-parametric survival analysis at the gene and splice variant level using 263 a previously published approach ("minimum p-value") and our new NEEP ("null 264 empirically estimated p-values") method, as described below. The clinical files 
where x is the greatest integer less than or equal to x. To determine a viable range 288 of thresholds, we first chose minimum power and effect size. Given a sample size of 432 289 patients with 151 recorded death events and an alpha of 0.1, to obtain a hazard ratio 290 greater than 2 (or less than 0.5) and a minimum power of 0.75, the survival curve with 291 fewest patients must have at least 62 members. This corresponds to a minimum 292 percentile threshold of 0.143, which we round in this study to 0.15 for simplicity. So, in 293 this study we set l to 0.15 and h to 0.85.
294
Considering the size of s, enumerating all possible p-values is computationally 295 unfeasible. Therefore, we built a null distribution with 1,000,000 Monte Carlo 296 simulations performed by randomly partitioning samples into the two groups using all 297 possible thresholds and extracting the smallest logrank test p-value. We estimated 298 p-values as the fraction of simulated values less than or equal to the minimum p-values 299 obtained from the actual data. As expected, the NEEP procedure yielded uniformly 300 distributed p-values. Benjamini-Hochberg adjustment was conducted on the NEEP 301 p-values, and adjusted values less than 0.1 were considered significant.
302
It is noteworthy to mention that individual expression values do not impact the KM 303 survival curve as long as they result in the same split between high and low expression. 304 Therefore, the NEEP procedure needs to be carried out only once for the whole set of 305 genes/splice variants, provided the fraction of patients expressing the gene/splice 306 variant is as large as or greater than 1 − l, the minimum percentile threshold. In our 307 dataset, this criterion was met by 21,100 genes and 69,561 splice variants. Thus, we 308 empirically estimated the p-values of these genes/splice variants using a single sampled 309 null distribution. While effect sizes of the logrank test are not as naturally interpretable 310 as many other statistical tests, we calculated the hazard rate ratio of high over low 311 expression curves as well as the mortality rates at 1, 2, and 5 years. Code for 312 constructing NEEP values from clinical and expression data and calculating effect size 313 statistics is available at https://github.com/thecodingdoc/neep. 324 We utilized data across multiple granularities to construct plausible graphs for the 325 association between splice variant expression and lung cancer survival. Specifically, we 326 used protein-protein interactions (PPI) from BioGRID [20] , domain-domain interactions 327 (DDI) from 3did [21] , splice variant domain prediction using HMMER3.1 [22] , and the 328 survival analysis significance values using NEEP, with the goal of identifying 329 cancer-specific changes in PPI interactions.
Multi-granular graphs
330
The general structure of these multi-granular graphs (MGG) can be seen in Fig 1. 
331
The outcome of the workflow consists of quadripartite networks, connecting splice 332 variants with their potential interaction partners via their domain-domain interaction, 333 as variant-domain-domain-variant paths.
334
To build these graphs, we extracted protein-protein interactions from BioGRID 
342
We identify two domain patterns of interest, "ghost" and "gained". Ghost domains 343 are those that are present in survival-insignificant splice variants within the same gene, 344 but are not found in the survival-significant splice variant. Gained domains are found in 345 the survival-insignificant splice variants but present in the survival-significant splice 346 variants. By incorporating these gained and ghost domains direct into their PPI 347 context, we can consider MGGs as potential interaction changes caused by domain 348 exclusion or inclusion. Genes without multiple splice variants were removed from 349 further analysis. We downloaded the 11,200 domain-domain interactions (DDI) from 350 3did [21] , where inclusion requires a known protein-protein structure to support the 351 interaction. Variant-domain membership was determined using HMMER3.1 [23] with 352 default parameters and the Pfam database [24] . After removal of interactions without 353 DDI support, 5912 interactions remained. Of these, only 1208 had gained or ghost 354 domains. There were 50 genes with an isoform significant for survival for these 1208 355 interactions. Code for constructing MGG interaction paths from variable data sources is 356 available at https://github.com/scwest/SINBAD.
357
Identification of significant COSMIC mutation signatures 358
To examine if the splice variant RAD51C-202 was associated with homologous 359 recombination mutations, we utilized COSMIC gene signatures [25] . We used the 360 optimal NEEP threshold of RAD51C-202 to separate the patients into a low expression 361 (344 patients) and high expression (88 patients) group. Mutation data for each patient 362 was downloaded from TCGA for all 4 variant callers: MuSE [26] , MuTect [27] , 363 SomaticSniper [28] , and VarScan [29] . Mutation profiles for each patient were 364 constructed as described as the 6 substitution types along with the neighboring bases 365 for a total of 96 mutation types using only mutations found by all four variant callers. 366 The Catalogue of Somatic Mutations In Cancer (COSMIC) has identified a set of 30 367 commonly identified mutation signatures deconvolved from cancer patient mutation 368 profiles [25] . We used MutationalPatterns [30] in R to find the linear contributions of 369 each of the 30 signatures to a patient profile. We used Mood's test for median to 370 determine if the contributions were significantly different between low and high 371 RAD51C-202 expression groups for each signature.
372
To check for possible confounding factors, we considered three smoking variables 373 May 3, 2019 12/16
reported by TCGA and checked whether they were different between the low and high 374 RAD51C-202 expression groups: cigarettes per day was tested using the Welch two 375 sample t-test; years smoked was tested using the Wilcoxon rank sum test; and the 376 binary smoker variable was tested using the two-sample test for equal proportions. In 377 addition, we checked if survival confounded the relationship between RAD51C-202 and 378 signature 3. Because the causality between mutations and survival must be directional, 379 we conducted Cox-PH survival analysis of RAD51C-202 with and without the 380 contribution of Signature 3 as a confounding variable. Further, Mood's test was also 381 conducted for the relationships between Signature 3 and the remaining splice variants 382 with MGGs. The exact binomial test was used to determine if the proportion of splice 383 variants significant for Signature 3 was greater than expected by chance.
384
Supporting information 385 S1 File. Enrichment analysis methods. 
